Overview

* Oncology Institute ( TOI ) Q3 revenue rises 36.7% yr/yr, driven by organic growth in Florida, Oregon

* Net loss for Q3 widens slightly to $16.5 mln compared to $16.1 mln last year

* The cancer clinics operator updates full-year revenue guidance to $495-$505 mln

Outlook

* Company updates full-year revenue guidance to $495 mln-$505 mln, from prior outlook of $460-$480 mln

* Company revises full-year Adjusted EBITDA guidance to $(11) mln-$(13) mln

* Company expects Q4 Adjusted EBITDA of $0 to $2 mln

Result Drivers

* ORGANIC GROWTH - Fee-for-service revenue grew 13% over Q3 2024, driven by organic growth in Florida and Oregon

* PHARMACY RECORDS - Retail Pharmacy and Dispensary set fill records, contributing $75.9 mln in revenue and $12.8 mln in gross profit

* NEW PROVIDERS - Signed several new in-network MSO providers in Florida and opened a new pharmacy location

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 EPS -$0.14

Q3 Net -$16.50

Income mln

Q3 Gross $18.90

Profit mln

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the healthcare facilities & services peer group is "buy"

* Wall Street's median 12-month price target for Oncology Institute Inc ( TOI ) is $7.00, about 51% above its November 12 closing price of $3.43

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)